ACTHRD™   PARP Inhibitors Treatment Selection


| ACTHRD™ Identifies Patients Who May Benefit from PARP Inhibitor Treatment: PARP inhibitors have made significant breakthroughs in personalized cancer treatment over the past few years. With the recent U.S. FDA approvals, genetic testing can now be used in patients with ovarian, breast, prostate, and pancreatic cancer to identify individuals who would likely benefit from PARP inhibitor treatment. | Key Features Complete Information on BRCA and HRR genes: ACTHRD™ is an NGS-based test covering the coding exons and splicing regions of BRCA1/2 and 22 HRR genes to detect SNV, InDel, and large genomic rearrangements (LGRs) CNVs, and LOH status. Up-to-date Bioinformatic Analysis based on International Databases: Bioinformatic analysis is carried out by a team of dedicated and experienced bioinformaticians with solid clinical genetics backgrounds. Information extracted from international databases such as gnomAD, 1000 Genome, ClinVar, COSMIC, and ACT Genomics’ self-built ethnographic database, provides relevant interpretation and valuable insights on the variants identified. A Clear and Detailed Medical Report: The report provides recommendations according to the latest ACMG Guidelines and AMP Guidelines and other relevant information such as disease risk based on the currently available clinical literature. Suitable Cancer Types: - Ovarian cancer - Prostate cancer - Breast cancer - Other solid tumors Short turnaround time: Providing a testing report in 10 working days.
Visit ID (prod)
ACT Genomics Co. Ltd.(Looking for distributors) Company IntroACT Genomics is a leading cancer genomic testing provider started in Taiwan in 2014. Now, we have grown and expanded into Japan, Singapore, Hong Kong, and the Southeast Asia region.With cutting-edge next-generation sequencing (NGS), proprietary bioinformatics analysis, and combined expertise in tumor biology, cancer genomics, bioinformatics, and artificial intelligence, our genomic tests provide treatment suggestions based on the tumor's genomic markup. With our tests, the doctors can formulate a personalized treatment plan to achieve a better outcome for their cancer patients.Our NGS-based TestsACTOnco® +: Tumor tissue-based (FFPE)Provides comprehensive genetic information on the potential therapeutic response (i.e. to targeted therapy, chemotherapy, immunotherapy)Incorporates pathway-based analysis for a holistic overview & therapeutic recommendations440 cancer-related genes (including 13 fusion genes)All types of solid tumors (lung, breast, colorectal, prostate, TNBC, pancreatic, ovarian, CCA, liver, glioblastoma, rare cancer, and other solid tumors)ACTHRD™:  Tumor tissue-based (FFPE)Determines BRCA 1/2, LOH, and HRD status for PARP inhibitor treatment24 HRR-related genes (including BRCA1/2)Ovarian cancer and HRD-/HRR-related cancer typesACTDrug® +:  Tumor tissue-based (FFPE)Focuses on clinically recommended biomarkers for targeted therapies40 actionable genes (including 13 fusion genes)Common cancer types: lung cancer, gastric cancer, colon cancer, prostate cancer, etc.ACTLung™: Tumor tissue-based (FFPE)Focuses on biomarkers associated with lung cancer for targeted therapy13 lung-cancer-related genes (including 8 fusion genes)Lung cancerACTMonitor® +:  Blood-based (ctDNA)Monitors disease burden and treatment response/resistance50 cancer-related genesSolid tumors (Pan-cancer)